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Signaling by the Wnt family of secreted glycolipoproteins plays key roles in 
embryonic development of organisms ranging from nematodes to mammals and is 
also implicated in several types of human cancers. Canonical Wnt signaling functions 
by regulating the translocation of -catenin to the nucleus, where it controls key gene 
expression programs through interaction with Tcf/Lef and other families of 
transcription factors. Wnts can also act through non-canonical pathways that do not 
involve -catenin activation, but implicate small GTPases/JNK kinase and 
intracellular calcium. 
Here we review recent studies that have revealed the expression of several 
components of Wnt/-catenin signaling in the adrenal cortex and discovered a key 
role for this pathway in the regulation of proliferation/differentiation of progenitor cells 
and in tumorigenesis of that endocrine organ.  
 
 











The adrenal gland contains a neuroendocrine medulla within a steroidogenic 
cortex. The medulla produces catecholamines in response to sympathetic inputs, 
while the cortex produces essential steroids in response to hormonal inputs. 
Aldosterone secretion from the adrenal cortex regulates sodium retention and plasma 
volume (Takeda, 2004; Whaley-Connell et al., 2010), and has been classically 
considered to be regulated by the renin–angiotensin system. Glucocorticoid output, 
which is an essential component of the stress response (Sapolsky et al., 2000), is 
modulated by the hypothalamic–pituitary–adrenal (HPA) axis. Although 
adrenocortical function requires precise control of the differentiation of steroidogenic 
cell lineages, the developmental and postnatal mechanisms that regulate their 
production and maintenance have only recently started to be defined (Kim and 
Hammer, 2007). 
Wnt signaling has been identified as one of the key signaling pathways in both 
normal development (regulating cell growth, motility and differentiation) and 
tumorigenesis. Deregulation of this pathway is in fact often present in human cancers 
(Kikuchi, 2003). Here, we will review what is known about the role of Wnt signaling in 
normal adrenal gland development and its alterations in adrenocortical tumors. 
 
 
Wnt signaling in development and function of the adrenal cortex 
 
Mechanisms of Wnt signaling  
Signaling by the Wnt family of secreted glycolipoproteins plays key roles in 
embryonic development of organisms ranging from nematodes to mammals. A 
critical and most studied Wnt pathway is the canonical Wnt signaling, which functions 
by regulating the amount of the transcriptional co-activator -catenin that controls 
essential developmental gene expression programs (for an exhaustive overview of 
Wnt signaling see the web resource 
http://www.stanford.edu/%7Ernusse/wntwindow.html). In the absence of Wnt, casein 
kinase 1 (CK1) and glycogen synthase kinase-3 (GSK-3) sequentially 
phosphorylate the amino terminal region of -catenin in the Axin complex, which is 
composed of the scaffolding protein Axin, the tumor suppressor adenomatous 










polyposis coli gene product (APC), CK1, and GSK-3 horylated -catenin is 
subsequently ubiquitinated, resulting in its proteasomal degradation. This continual 
elimination of -catenin by the action of the Axin complex keeps its level low, 
preventing it from reaching the nucleus, and Wnt target genes are thereby repressed 
by the DNA-bound T cell factor/lymphoid enhancer factor (Tcf/Lef) family of proteins 
complexed with Groucho/TLE corepressors. The Wnt/-catenin pathway is activated 
when a Wnt ligand binds its cell-surface receptor consisting of a seven-pass 
transmembrane Frizzled (Fz) receptor and its co-receptor, low-density lipoprotein 
receptor related protein 6 (LRP6) or its close relative LRP5. The formation of a likely 
Wnt-Fz-LRP6/5 complex together with the recruitment of the scaffolding protein 
Dishevelled (Dvl), which antagonizes the action of GSK-3 through an unknown 
mechanism, results in the inhibition of -catenin phosphorylation. At that stage -
catenin dissociates from the Axin complex and is no longer degraded, accumulating 
in the cytoplasm and also being translocated to the nucleus, where it competes with 
Groucho/TLE corepressors for binding to Tcf/Lef (Daniels and Weis, 2005), thereby 
stimulating the expression of various Wnt target genes (Huang and He, 2008; 
MacDonald et al., 2009; Mulholland et al., 2005; van Amerongen and Nusse, 2009). 
This constitutes the most widely accepted current model of Wnt/-catenin signaling 
(Figure 1). To increase the complexity of the system, Wnts can also act through "non-
canonical" pathways that do not involve -catenin activation, but implicate small 
GTPases/JNK kinase and intracellular calcium (Rao and Kuhl, 2010). Additionally, 
natural antagonists of Wnt signaling exist, which can bind either to 1) Wnt proteins or 
to 2) their receptors. Some of the most prominent members of the first class are 
secreted Frizzled-related proteins (sFrp), which display a high sequence homology 
with the extracellular Wnt binding domain of Frizzled in their N-terminal region and 
function as Wnt antagonists for both canonical and non-canonical signaling (Kawano 
and Krypta, 2003), while Dickkopf family members encode secreted proteins which 
antagonize Wnt signaling by inhibiting the Wnt coreceptors LRP5 and 6 (Niehrs, 
2006). 
 
Zonal patterns of expression of Wnt-related genes in the adrenal cortex 
A role for Wnt signaling in the development of the adrenal cortex is suggested 
by the zonal expression of several of its component elements. Wnt4 is a signaling 










factor with multiple roles in organogenesis (Brisken et al., 2000; Jordan et al., 2003; 
Vainio et al., 1999). Its deficiency leads to abnormal development of the kidney, 
pituitary gland, female reproductive system, and mammary gland. Wnt4 is expressed 
in the cortical region of the developing adrenal gland from embryonic d11.5 onward, 
especially in the outermost part, the zona glomerulosa. Its expression correlates 
temporally with that of the transcription factor Sf1 (see below). Wnt4-deficient mice 
have a smaller number of glomerulosa cells, which leads to a decrease in the 
production of aldosterone. Such a defect in aldosterone biosynthesis is associated 
with an abnormal distribution of aldosterone synthase, Cyp11b2, in the adrenal 
(Heikkila et al., 2002). Cyp11b2 is the terminal enzyme in the pathway of aldosterone 
biosynthesis and is normally confined to the zona glomerulosa. 
The -catenin, a downstream effector of Wnt signaling, can 
serve as a marker for Wnt pathway activation. Nuclear -catenin expressing cells are 
localized in a subcapsular position in the mouse adrenal cortex (Figure 2). Eberhart 
and Argani have published a survey of -catenin nuclear localization in normal 
human fetal and adult tissues in which they have shown its localization in the 
glomerulosa of the adrenal cortex (Eberhart and Argani, 2001). Knockout (KO) mice 
that are globally deficient in β-catenin undergo embryonic lethality during gastrulation 
and lack mesoderm, precluding analysis of potential defects in adrenal development 
(Haegel et al., 1995). To get further insight into the role of β-catenin in the adrenal 
cortex, recent studies shutting down -catenin expression through the use of a Sf1 
promoter-Cre transgene in adrenocortical cells produced mice with either complete 
adrenal aplasia or defects in maintenance of the adult cortex resulting in depletion of 
adrenocortical cells (Kim et al., 2008). These results show the essential role of β-
catenin in mouse adrenocortical development. At least part of this phenotype may be 
attributed to the lack of -catenin function in cell-cell adhesion and be independent of 
Wnt signaling, since this defect is considerably more severe than that seen in Wnt4-
deficient mice (Heikkila et al., 2002). However, Wnt4 may have additional roles in 
noncanonical Wnt signaling (Brisken et al., 2000; Vainio et al., 1999), the canonical 
pathway may be activated by additional Wnt ligands in the adrenal gland, or β-
catenin activation may be the target of other, Wnt-independent signaling pathways 
(Hino et al., 2005; Taurin et al., 2006). 










Gene expression profiling studies on human and mouse adrenal glands have 
shown that among the Dickkopf factors only Dkk3 was expressed at a detectable 
level. In situ hybridization on adult human adrenal gland sections showed that Dkk3 
is differentially expressed with a higher expression in the zona glomerulosa than in 
the zona fasciculata or the zona reticularis (Suwa et al., 2003). Studies screening for 
expression of other gene families involved in the Wnt pathway, the frizzled (Fz) and 
dishevelled (Dvl) families, in the adrenal cortex have reported that Fz1, Fz2 and Dvl3 
transcripts are found in human, whereas only Fz2 and Dvl3 are present in the mouse 
(Suwa et al., 2003). Recently, Bernichtein et al. have also reported the presence of 
Sfrp1 mRNA expression in mouse adrenal gland and assessed its expression by 
immunohistochemistry, showing an intense staining for the sFrp1 protein throughout 
the adrenal cortex (Bernichtein et al., 2008). 
To summarize, Wnt4 and -catenin expression in mice and DKK3 expression in 
human are confined to the zona glomerulosa, whereas Sfrp1 is distributed throughout 
the whole cortical region of the mouse adrenal. The colocalization of Wnt4 and -
catenin in the glomerulosa implies an action of the canonical Wnt signaling pathway 
on glomerulosa-specific function, which is probably locally limited by a potential 
inhibitor like DKK3. Altogether, these data show that a variety of genes of the Wnt 
signaling pathways are expressed in the adrenal cortex and suggest a role for Wnt 
signaling in the development and/or maintenance of functional zonation in the 
adrenal cortex. 
 
Effect of -catenin on SF-1-mediated transcription 
Steroidogenic Factor-1 (SF-1) is a critical regulator of adrenogonadal 
development and function. Its overexpression also has an important role in the 
pathogenesis of adrenocortical tumors (reviewed in Schimmer and White, 2010; Lalli, 
2010). -catenin has been shown to physically associate with SF-1 and increase its 
transactivation of several gene promoters (Hossain and Saunders, 2003; Jordan et 
al., 2003; Mizusaki et al., 2003). One report also showed that in the testis Wnt4 
represses steroidogenesis by antagonizing SF-1/-catenin synergy (Jordan et al., 
2003). Thes -catenin also plays important roles in 
adrenocortical function through the modulation of SF-1 action.  
 










Action of Wnt signaling components on steroidogenesis 
Dkk3 and Wnt4 have multiple actions on steroidogenesis in normal human 
adrenocortical cells, including effects on overall steroidogenesis (aldosterone and 
cortisol biosynthesis) and distinct effects on steroidogenic enzyme mRNA levels. 
Dkk3 inhibits aldosterone and cortisol biosynthesis in primary human adrenocortical 
cells, both in basal conditions or in the presence of cyclic AMP (cAMP) (Chen and 
Hornsby, 2006). Conversely, Wnt4 increases steroidogenesis, as evidenced by the 
increase of both Cyp17 and Cyp21 when added alone, but decreases it in the 
presence of cAMP (Chen and Hornsby, 2006). Dkk3 also decreases cAMP-
stimulated Cyp17 expression. Both Dkk3 and Wnt4 increase the level of Cyp11b2. 
Overall, these data indicate that the overlap of Dkk3 expression with Wnt4 and -
catenin in the zona glomerulosa and the stimulation of Cyp11b2 by Dkk3 and Wnt4 
might imply an action on glomerulosa-specific function. 
 
 
Wnt signaling in adrenocortical tumors 
 
Adrenocortical tumors (ACTs) in the literature refer to both adrenocortical 
adenoma (ACA) and adrenocortical carcinoma (ACC), even though they are different 
entities. ACA are frequent in the general population and nowadays they are most 
often found incidentally, while ACC is a rare tumor with 2 peaks occuring mostly in 
the first decade of life as well as in the fourth and fifth decades, with an incidence of 
4-12 per million per year in adults (Bertherat and Bertagna, 2009). They are more 
common in women. ACTs have been classified as either functional (75%) or 
nonfunctional (25%) tumors, depending on hormone hypersecretion syndromes. In 
contrast to adult tumors, over 95% of pediatric tumors are functional and are 
frequently associated with congenital abnormalities and secondary tumors. 
Functional tumors produce symptoms depending on their production of an excess of 
glucocorticoid (Cushing’s syndrome), androgen (virilization) or mineralocorticoid 
(Conn’s syndrome) hormones. It is difficult to distinguish between benign and 
malignant ACTs. However, a number of criteria can be applied, including size: benign 
tumors of the adrenal cortex are generally smaller than malignant tumors. The 
presence of distant metastases is an absolute indication of malignancy.  










Although our understanding of ACT biology has increased after the results obtained 
by analysis of their gene expression profiles (de Reyniès et al., 2009; Giordano et al., 
2003; Giordano et al., 2009; West et al., 2007) the precise sequence of events 
involved in their pathogenesis remains to be elucidated. Adrenocortical 
tumorigenesis in rodents and humans involves both genetic and epigenetic 
alterations, with accumulation of chromosomal alterations being a key mechanism 
during tumor progression.  
 
Mutations of APC and adrenocortical tumors 
Genetic alterations of the Wnt signaling pathway were initially identified in 
patients with familial adenomatous polyposis coli (FAP) and have since then been 
extended to a variety of cancers. Patients with FAP have constitutive activation of the 
Wnt/β-catenin signaling pathway due to germline loss-of-function mutations of the 
APC gene. They are predisposed to both colonic and extra-colonic tumors, among 
which adrenocortical tumors. Interestingly, most of these ACT in patients with FAP 
are benign and reveal no mutations in the -catenin gene (Schinner et al., 2009; 
Smith et al., 2000). 
 
-catenin and adrenocortical tumors 
It has been reported that activating mutations of exon 3 of the -catenin gene 
(CTNNB1), encoding a specific serine/threonine rich domain which is phosphorylated 
by GSK-3β and is essential for the targeted degradation of β-catenin, are found in a 
wide variety of human cancers including adrenocortical tumors (Gaujoux et al., 2008; 
Polakis, 2000; Tadjine et al., 2008a; Tadjine et al., 2008b; Tissier et al., 2005). These 
mutations were reported with similar frequencies in ACAs and ACCs. However, 
abnormal cytoplasmic or nuclear immunolocalization of -catenin was observed in 
85% of adrenocortical carcinomas compared to 38% of ACAs (Tissier et al., 2005). 
Similarly, a somatic mutation of -catenin has been observed in a heterogeneous 
ACT with an apparently benign part adjacent to a malignant one. The catenin 
mutation was localized only in the malignant part of this tumour, suggesting that its 
occurrence would be associated with a more aggressive ACT (Gaujoux et al., 2008). 
-catenin nuclear accumulation produces consequent activation of Tcf/Lef 
transcription factors, which induce expression of c-myc and/or cyclin D genes, as 










reported in colon cancer cell lines (He et al., 1998; Tetsu and McCormick, 1999). 
Moreover, knock-down of -catenin blocks colon cancer cells in G1, providing proof 
of principle that interference with aberrant Wnt signaling could be of therapeutical 
value (van de Wetering et al., 2003). In addition, β-catenin immunoreactivity has also 
been observed in the nuclei of neoplastic cells that accumulate in the adrenal cortex 
of gonadectomized inbred mice, suggesting that the Wnt signaling pathway may 
participate in gonadectomy-induced adrenocortical neoplasia (Bielinska et al., 2005). 
Berthon et al. have recently developed transgenic mice expressing a constitutively 
active -catenin in their adrenal cortex. These mice show adrenal hyperplasia and 
dysplasia and develop malignant tumors over a 17-month time course. Moreover, 
profound changes in cellular and zonal adrenocortical identity are present. They 
manifest as ectopic differentiation of Cyp11b2-expressing cells at the expense of 
fasciculata cells, leading therefore to primary hyperaldosteronism. These data 
demonstrate that constitutively active -catenin is an adrenal oncogene which can 
trigger aberrant differentiation of aldosterone-secreting cells and promotes 
malignancy (Berthon et al., 2010). Of note, the H295R adrencortical cancer cell line 
harbors a -catenin-activating mutation. This leads to constitutive -catenin-
dependent transcription. Treatment of this cell line with the Tcf/β-catenin antagonist 
PKF115-584 inhibits the transcriptional effect of -catenin and decreases cell 
proliferation (Doghman et al., 2008). Altogether these findings establish the Wnt 
signaling pathway as a potential herapeutic target in patients with adrenocortical 
tumors displaying abnormal -catenin accumulation.  
 
Secreted Frizzled-related proteins (sFrps) and adrenocortical tumorigenesis 
Alterations in the levels of sFrps expression caused by hypermethylation of 
their promoter region are among the most frequently occurring epigenetic alterations 
in different pathological conditions including tumor formation and make these 
molecules relevant to investigations in diverse fields of biology and biomedical 
sciences. Such epigenetic alterations are associated with transcriptional gene 
silencing (Baylin and Herman, 2000; Feinberg and Tycko, 2004) and put the spotlight 
on the study of the correlations between sFrps and human cancer development.  
Sfrp1 and/or Sfrp2 hypermethylation seems to occur in a wide variety of tumor 
types (Dahl et al., 2007; Huang et al., 2007; Lodygin et al., 2005; Suzuki et al., 2004; 










Suzuki et al., 2008). It has been therefore proposed, at least for bladder carcinomas, 
that the status of Sfrp1 promoter methylation could serve as an epigenetic biomarker 
for cancer detection and progression (Lee et al., 2004; Veeck et al., 2006). Although 
Sfrp1 re-expression in breast, hepatocellular and prostate tumors, where Sfrp1 had 
been inactivated, induces apoptosis and suppresses cell proliferation, the incidence 
of spontaneous tumor formation is not increased in Sfrp1 null mice (Trevant et al., 
2008). These data suggest that Sfrp1, and possibly the related Sfrp2 gene, act as 
tumor suppressor genes. Their inactivation may predispose to neoplastic progression 
rather than to tumorigenesis and other additional genetic alterations would in this 
case be necessary for tumor onset. It is remarkable that, in the gonadectomized mice 
adrenocortical tumor model, linkage studies have evidenced Sfrp1 as a candidate 
gene positively influencing tumorigenesis (Bernichtein et al., 2008). In these mice, 
Sfrp1 levels are lower in the tumor tissue compared to the adjacent normal adrenal 
cortex. Given the oncogenic potential of constitutive Wnt signaling, it has been 
generally accepted that antagonism of Wnt/-catenin signaling constitutes the 
mechanism by which Sfrp1 inhibits tumor cell growth and prevents metatastatic 
invasion (Esteve and Bovolenta, 2010). In contrast to these anti-tumorigenic effects 
of Sfrp1, other groups suggested that it can also act as an oncogene that is 
responsible for the metastatic properties of renal carcinoma and promotes prostate 
carcinogenesis (Joesting et al., 2005). This dual function suggests that the cellular 
context is an important determinant of Sfrp1 activity. Also, studies in colorectal 
tumors showed that another Sfrp gene, Sfrp4, may not act as a tumor suppressor 
gene and have quite different biological properties compared to other Sfrp family 
members (Feng Han et al., 2006).  
In summary, the fact that several oncogenes are Wnt responsive genes 
argues for the involvement of constitutive Wnt signaling in the development of cancer 
after the shutting down of Sfrp1 expression. It is thus evident that studies of the 
interactions between the different sFrp molecules and Wnt-related proteins will be of 
key importance to clarify the role of this family of soluble factors in tumor 
pathogenesis. These studies will also open the possibility for development of novel 
therapeutic approaches that target this pathway.  
 
 
Conclusions and perspectives 











The Wnt/-catenin pathway plays an important role in the regulation of the 
stem/progenitor cell pool and of the differentiation process in several tissues (Katoh, 
2007). Remarkably, in the gonads, which share a common embryological origin with 
the adrenal gland, activation of the Wnt/-catenin pathway has an essential role in 
regulating ovarian differentiation (Chassot et al., 2008; Liu et al., 2009; Maatouk et 
al., 2008; Tomizuka et al., 2008). Studies in the mouse have shown that -catenin is 
involved in the regulation of proliferation and differentiation of progenitor cells in the 
adrenal cortex and that its constitutive activation may lead to tumor formation 
(Berthon et al., 2010; Kim et al., 2008). We believe that now among the most relevant 
questions to be addressed are the following: 
- What is the nature of the Wnt factors responsible for-catenin activation in the 
subcapsular area of the adrenal cortex? Are other, Wnt-independent mechanisms 
involved? 
- How does -catenin crosstalk with other signaling pathways (growth factors, 
hedgehog, Notch) to regulate the size of the progenitor cell population and their 
differentiation?  
-  What is the precise relationship of Wnt signaling with adrenal cell differentiation 
into aldosterone-producing cells?  
- An interesting study reported regulation of downstream components of Wnt 
signaling at the post-transcriptional level by miRNAs in PPNAD, a benign neoplasm 
of the adrenal cortex (Iliopoulos et al., 2009). Can miRNAs regulate Wnt signaling 
also during normal development and in other pathological settings?  
 
It is easy to predict that in the years to come we shall witness a burgeoning of studies 
concerning the Wnt/-catenin pathway in the adrenal cortex that will considerably 
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Figure 1. The canonical Wnt signaling pathway. Binding of secreted Wnt factors to 
Frizzled receptors on the cell membrane transduces a signal to the Axin complex that 
inhibits phosphorylation, and then degradation, of -catenin. It then accumulates in 
the cytoplasm and can translocate in the nucleus, where it interacts with Tcf/Lef and 
other families of transcription factors to regulate expression of target genes.  
 
Figure 2. Immunostaining of -catenin in the mouse adrenal cortex. Nucleo-
cytoplasmic accumulation of -catenin is found in the subcapsular zone and in the 
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